Can a shoulder cartilage defect be treated without surgery?

Surgery is not the only option for a focal shoulder cartilage lesion. For suitable patients, a focal full-thickness defect in the glenohumeral joint can now be addressed through an ultrasound-guided outpatient injection — no theatre admission, no general anaesthetic, and no surgical incision required.

ChondroFiller (also marketed as Liquid Cartilage) is a CE-marked injectable collagen scaffold designed specifically for this purpose. The treatment is delivered as an in-clinic appointment under real-time ultrasound imaging, and the shoulder is an explicitly approved indication alongside the knee, hip, ankle, elbow, and wrist.

That said, not every shoulder cartilage problem qualifies. ChondroFiller is intended for focal, well-defined lesions rather than widespread joint degeneration, and a proper clinical assessment — including MRI — is needed to confirm suitability. The sections below set out how the treatment works, who it is and is not suited to, and what the available evidence shows.

How ChondroFiller works as an injectable scaffold

The collagen gel inside the syringe contains no donor cells and requires no laboratory preparation — ChondroFiller is an acellular scaffold, meaning its job is to create the right environment for repair rather than to deliver repair cells itself.

Once placed into the cartilage defect, the liquid collagen self-polymerises within roughly five to ten minutes, forming a stable three-dimensional gel that conforms to the shape of the lesion and sits flush with the surrounding cartilage surface. Precision here matters: a scaffold placed flush allows smooth loading across the joint, whereas overfilling can steer repair tissue towards fibrous rather than hyaline-like cartilage.

The gelled matrix then does something more than simply fill a gap. It acts as a chemotactic scaffold — drawing the patient's own mesenchymal progenitor cells inward from the synovial lining and the subchondral bone beneath the defect. Those recruited cells are guided by the collagen architecture to differentiate into chondrocyte-like cells, which progressively lay down hyaline-like repair tissue as the scaffold itself degrades. This cycle of scaffold resorption and endogenous tissue formation takes approximately 12 months to complete.

This mechanism — acellular matrix-induced chondrogenesis — distinguishes the approach from microfracture, which stimulates a repair response but without a structural scaffold, typically producing fibrocartilage rather than hyaline-like tissue. It also differs from autologous chondrocyte implantation (ACI), which requires an initial tissue-harvest procedure, a period of laboratory cell culture, and a second procedure to implant the expanded cells. ChondroFiller achieves its effect in a single session.

Which shoulder patients are usually assessed for this treatment?

Eligibility depends on the nature of the cartilage lesion, not on age or symptom severity alone — and a specialist assessment with imaging is the only reliable way to confirm it.

The lesion profile that is typically assessed

Candidates are usually patients with a focal, full-thickness chondral defect — ICRS Grade III or IV — in the glenohumeral joint, where the surrounding cartilage borders remain intact. MRI is the essential gatekeeping step: it confirms the lesion's size, depth, and boundary characteristics before any treatment decision is made. Some clinics apply no fixed upper size ceiling for the injectable route, though the broader cartilage restoration literature cites approximately 6 cm² as an indicative upper boundary for scaffold approaches.

Common exclusions

• Diffuse glenohumeral osteoarthritis or bone-on-bone joint space narrowing — ChondroFiller is a focal repair scaffold, not an end-stage OA treatment
• Active joint infection
• Inflammatory arthropathy in an acute flare
• Known allergy to collagen components

Why the diagnostic stage matters so much in the shoulder

Shoulder cartilage damage is genuinely difficult to identify without imaging. Aching at rest, pain on movement, and grinding sounds overlap almost entirely with rotator cuff tears, subacromial impingement, and labral pathology. A symptom checklist cannot distinguish between them. Specialist review of MRI findings — rather than symptom pattern alone — is what separates a focal chondral lesion from these other presentations and determines whether ChondroFiller is the appropriate pathway.

What the clinical evidence shows — and where gaps remain

The outcome data for ChondroFiller sits on a gradient of confidence: robust at the knee, promising at the hip, and — for the shoulder specifically — drawn by extrapolation rather than direct study.

What the knee evidence shows

The largest body of peer-reviewed data concerns the knee. Across manufacturer-sponsored investigations and independent series, patient-reported function scores (IKDC) improve by approximately 30 points over 12–36 months, and MRI repair quality scores (MOCART) consistently fall in the 70–87 range — indicating durable, structurally sound tissue formation. Aggregated across all joint applications, clinical evaluation data report that 70–85% of treated patients achieve meaningful symptom relief at three to five years.

The hip evidence — promising, but early

The only peer-reviewed technique paper focusing on a non-knee joint is a 2021 study by Perez-Carro et al. (PMC8322278), which describes arthroscopic delivery of ChondroFiller into full-thickness acetabular defects. The authors report promising early results but are explicit that longer follow-up is needed before firm conclusions can be drawn. It is an arthroscopic hip study, not a shoulder study.

The shoulder-specific gap

No published randomised trial or case series reporting shoulder-specific ChondroFiller outcomes has been identified. Shoulder evidence is currently extrapolated from knee, hip, and multi-joint cohort data — a reasonable starting point given that the device, mechanism, and CE indication are the same across joints, but an extrapolation nonetheless. The available evidence is also predominantly manufacturer-sponsored. Patients and clinicians considering this pathway should factor both of these limitations into their shared decision-making.

The treatment pathway: what to expect at an outpatient appointment

Attending an outpatient appointment for ChondroFiller takes most patients a few hours at most — there is no theatre admission, no general anaesthetic, and no surgical incision.

On the day

You will be seen by a specialist who reviews your MRI findings and confirms the injection plan before any procedure begins. The injectable scaffold is placed directly into the cartilage defect under real-time ultrasound imaging, which allows precise, millimetre-level positioning of the needle tip. Once the collagen is delivered into the lesion, it self-gels within minutes, conforming to the shape of the defect and bonding to the surrounding cartilage. You leave the clinic the same day.

After the injection

Post-injection guidance will cover activity modification and how much load you place on the shoulder while the scaffold integrates. Early improvement is often gradual rather than immediate — the collagen matrix takes time to recruit the body's own progenitor cells and build repair tissue, a process that consolidates over roughly 12 months. Meaningful symptom benefit is generally reported from six to twelve months onward rather than in the early weeks.

A follow-up MRI is typically arranged at an appropriate interval to assess how well the scaffold has integrated and to evaluate the quality of the repair tissue that has formed. Specific timing is determined by the treating specialist based on individual progress.

Access, cost, and finding a specialist

ChondroFiller holds CE-marking as a Class III medical device and is an approved treatment in the UK. It does not carry FDA approval and is not available through the NHS; major UK private insurers, including Bupa and AXA, do not routinely cover it either. Treatment is self-funded, and guide costs vary according to clinic and clinical complexity — patients should confirm current pricing directly with the treating specialist before proceeding.

Before booking a consultation, it is worth asking a few practical questions: whether the specialist has specific experience with glenohumeral cartilage assessment, whether the clinic offers ultrasound-guided scaffold placement as its current delivery route, and what MRI reporting pathway is in place before and after treatment. These are reasonable questions for any specialist who lists this treatment.

Search MSK lists specialists across the UK who offer ChondroFiller and injectable cartilage scaffold treatments — the directory can be filtered by region and specialty to identify a suitably qualified clinician near you.